Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.

Ch Dittrich; G Greim; M Borner; K Weigang-Köhler; H Huisman; A Amelsberg; A Ehret; J Wanders; A Hanauske; P Fumoleau

doi:10.1016/S0959-8049(02)00020-5

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.

Ch Dittrich
, G Greim
, M Borner
, K Weigang-Köhler
, H Huisman
, A Amelsberg
, A Ehret
, J Wanders
, A Hanauske
, P Fumoleau

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

63 Citations (Web of Science)

Original language	English
Pages (from-to)	1072-1080
Journal	EUROPEAN JOURNAL OF CANCER
Volume	38
Issue number	8
DOIs	https://doi.org/10.1016/S0959-8049(02)00020-5
Publication status	Published - 2002

Keywords

THERAPY
GLYCOPROTEIN
CARCINOMAS
ANTIBODIES
DISEASE

Access to Document

10.1016/S0959-8049(02)00020-5

Cite this

Dittrich, C., Greim, G., Borner, M., Weigang-Köhler, K., Huisman, H., Amelsberg, A., Ehret, A., Wanders, J., Hanauske, A., & Fumoleau, P. (2002). Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. EUROPEAN JOURNAL OF CANCER , 38(8), 1072-1080. https://doi.org/10.1016/S0959-8049(02)00020-5

Dittrich, Ch ; Greim, G ; Borner, M et al. / Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. In: EUROPEAN JOURNAL OF CANCER 2002 ; Vol. 38, No. 8. pp. 1072-1080.

@article{c9f66ccca11c43b992718a0e37f2da98,

title = "Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.",

keywords = "THERAPY, GLYCOPROTEIN, CARCINOMAS, ANTIBODIES, DISEASE",

author = "Ch Dittrich and G Greim and M Borner and K Weigang-K{\"o}hler and H Huisman and A Amelsberg and A Ehret and J Wanders and A Hanauske and P Fumoleau",

year = "2002",

doi = "10.1016/S0959-8049(02)00020-5",

language = "English",

volume = "38",

pages = "1072--1080",

journal = "EUROPEAN JOURNAL OF CANCER ",

issn = "0959-8049",

publisher = "Elsevier ",

number = "8",

}

Dittrich, C, Greim, G, Borner, M, Weigang-Köhler, K, Huisman, H, Amelsberg, A, Ehret, A, Wanders, J, Hanauske, A & Fumoleau, P 2002, 'Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.', EUROPEAN JOURNAL OF CANCER , vol. 38, no. 8, pp. 1072-1080. https://doi.org/10.1016/S0959-8049(02)00020-5

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. / Dittrich, Ch; Greim, G; Borner, M et al.
In: EUROPEAN JOURNAL OF CANCER , Vol. 38, No. 8, 2002, p. 1072-1080.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.

AU - Dittrich, Ch

AU - Greim, G

AU - Borner, M

AU - Weigang-Köhler, K

AU - Huisman, H

AU - Amelsberg, A

AU - Ehret, A

AU - Wanders, J

AU - Hanauske, A

AU - Fumoleau, P

PY - 2002

Y1 - 2002

KW - THERAPY

KW - GLYCOPROTEIN

KW - CARCINOMAS

KW - ANTIBODIES

KW - DISEASE

U2 - 10.1016/S0959-8049(02)00020-5

DO - 10.1016/S0959-8049(02)00020-5

M3 - Original Article

C2 - 12008195

SN - 0959-8049

VL - 38

SP - 1072

EP - 1080

JO - EUROPEAN JOURNAL OF CANCER

JF - EUROPEAN JOURNAL OF CANCER

IS - 8

ER -

Dittrich C, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. EUROPEAN JOURNAL OF CANCER . 2002;38(8):1072-1080. doi: 10.1016/S0959-8049(02)00020-5